Anti-LGALS9 / Galectin 9, clone LGALS9/7689

0.2 mg/ml in 1X PBS with 0.05% BSA, 0.05% sodium azide. LGALS9 Antibody recognizes Galectin 9, also known as Lectin galactoside-binding soluble 9, a beta-galactoside-binding lectin encoded by the LGALS9 gene. Galectin 9 antibody is widely referenced in immunology literature as LGALS9 antibody and Gal-9 antibody due to its established role in immune regulation and tumor immunology. Galectin 9 belongs to the galectin family of carbohydrate-binding proteins characterized by conserved carbohydrate recognition domains that bind beta-galactoside-containing glycoconjugates.Galectin 9 is expressed in a variety of immune and epithelial cell types and can localize to the cytoplasm, nucleus, and extracellular space depending on cellular context. Structurally, Galectin 9 contains two tandem carbohydrate recognition domains connected by a linker peptide, allowing it to crosslink glycoproteins on the cell surface. This structural organization enables Galectin 9 to modulate cell adhesion, apoptosis, and immune checkpoint signaling pathways. LGALS9 antibody is commonly used in studies evaluating Galectin 9 expression in inflammatory diseases, viral infections, and cancer microenvironments.Functionally, Galectin 9 is best known for its interaction with immune regulatory receptors such as TIM-3, influencing T cell exhaustion, tolerance, and immune homeostasis. Through these interactions, Galectin 9 participates in the regulation of innate and adaptive immune responses. Altered expression of LGALS9 has been reported in multiple tumor types, where Galectin 9 expression may correlate with immune infiltration and tumor immune evasion mechanisms. As a result, Galectin 9 antibody is frequently utilized in tumor immunology and biomarker research settings.Beyond immune modulation, Galectin 9 has been implicated in cell aggregation, apoptosis induction, and regulation of cytokine production. Differential expression patterns across tissues and disease states make LGALS9 Antibody a valuable tool for examining Galectin 9 distribution and its role in immune checkpoint biology, inflammatory signaling, and cancer-associated immune landscapes.